Fixed dose (phase 2)
Trial- Dose
- 1, 3, 6 or 9 mg
- How often
- Once weekly
- How long
- 48 weeks
Started at the full dose. 9 mg gave 20.1% mean loss vs 0.4% on placebo, if all stayed on treatment, but nausea (33%) and fatigue (43%) were common.
Human studiesSelective amylin receptor agonist
Eloralintide
LY3841136
- Common dose
- 1–9 mg weekly (trials)
- Cycle
- Continuous
- Form
- In trials only
An investigational once-weekly injection that copies amylin, a fullness hormone the pancreas releases with insulin, and acts mainly on the amylin 1 receptor. It reduces appetite and food intake.
Evidence. Investigational (Eli Lilly). In a 48-week phase 2 trial of 263 adults without diabetes, weekly doses lowered weight 9.4–20.1% vs 0.4% on placebo, if everyone had stayed on treatment; a 48-week trial in type 2 diabetes reported 8.2–12.3% vs 3.0% (press release, September 2026). Phase 3 trials (ENLIGHTEN) began in December 2025; not approved anywhere as of October 2026.
What it’s used for
None of these uses is approved. Uses tested in people come first, then claims that rest on animal studies or user reports.
- Weight loss in obesity or overweight
- TrialPromising, not approved: in a 48-week phase 2 trial of 263 adults without diabetes, weekly doses cut weight 9.4–20.1% vs 0.4% on placebo, if everyone had stayed on treatment.
- Weight loss with type 2 diabetes
- TrialPositive, not approved: in a 48-week trial of 367 adults with type 2 diabetes, it cut weight 8.2–12.3% vs 3.0% on placebo, if all stayed on treatment (press release, September 2026).
- Blood sugar in type 2 diabetes
- TrialIn the same trial, HbA1c (average blood sugar) fell 1.1–1.4 points vs 0.3 on placebo at 48 weeks. Reported by press release only; not yet published.
- Weight loss with tirzepatide
- TrialWith tirzepatide, weight fell up to 23.3% vs 14.8% on tirzepatide 15 mg alone at 48 weeks in type 2 diabetes, with more side effects (press release). Not approved.
- Sleep apnea and knee osteoarthritis pain
- No studyUnproven: 64-week phase 3 trials in obstructive sleep apnea and in knee osteoarthritis pain began in February 2026, with results expected in 2028.
- Gentler on the stomach than GLP-1 drugs
- No studyUnproven: no trial has compared them head to head. In phase 2, nausea hit 11–64% depending on dose and starting schedule, and fatigue up to 46%.
Trial: tested in people, with the result. No study: nothing published supports it.
Every compound’s uses, by body system: evidence map, and by condition: conditions A to Z.
Status
- Approval
- Not approved in the US or anywhere else. Eli Lilly began phase 3 trials (ENLIGHTEN) in December 2025; none has reported yet.
- US compounding
- Never nominated for FDA’s 503A or 503B bulk lists and not in any of FDA’s compounding categories (lists updated May 2026 and March 2025). It isn’t part of any approved drug, so it can’t legally be compounded.
- European Union
- No marketing authorization; it is still in clinical trials.
- United Kingdom
- No marketing authorization; it is still in clinical trials.
- Canada
- No marketing authorization; Health Canada’s Drug Product Database lists no eloralintide product.
- Australia
- No product registered, and eloralintide isn’t named in the Poisons Standard (October 2026).
- Sport (WADA 2026)
- Likely banned in sportNot named on WADA’s 2026 list, but its S0 rule bans drugs with no current human approval anywhere, at all times.
- In the news
- September 30, 2026: Eloralintide plus tirzepatide beats tirzepatide alone in type 2 diabetes. Research digest
Category 2 is FDA’s list of bulk substances that may present significant safety risks in compounding. The 503A bulks list adds substances that pharmacies may compound with. Advisory committee votes are advice; FDA makes the final decision. Sport status follows the WADA Prohibited List in force since January 1, 2026; athletes should confirm with their anti-doping organization. Checked October 5, 2026. Status outside the US checked October 7, 2026 against EMA, MHRA, Health Canada and TGA records. By country: EU, UK, Canada, Australia. Status of every compound.
How it works
Eloralintide is a long-acting copy of amylin, a hormone the pancreas releases with insulin after meals. In cell studies it switched on the amylin 1 receptor about 12 times more strongly than the closely related calcitonin receptor. Natural amylin signals fullness to the brain and slows stomach emptying. In trials it lowered appetite and weight, and a fatty-acid chain keeps it in the blood for about two weeks.
TrialMainly from studies in people.
Not known
Whether its receptor selectivity means fewer side effects than other amylin drugs hasn’t been tested head to head, and why it slows the heart rate isn’t known. Safety beyond 48 weeks is unknown.
Protocol
Trial
Billings 2025
Obesity without diabetes (phase 2): 1, 3, 6 or 9 mg once weekly from the first dose, or stepped up to 9 mg (6 mg for 20 weeks, or 3 and 6 mg for 4 weeks each). At 48 weeks weight fell 9.4–20.1% vs 0.4% on placebo, if everyone had stayed on treatment.
Trial
Lilly press release, Sept 2026
Type 2 diabetes (phase 2): eloralintide alone at target doses of 3, 6 or 9 mg weekly; all arms started at 1 or 3 mg. At 48 weeks weight fell 8.2–12.3% vs 3.0% on placebo, if everyone had stayed on treatment.
Trial
Bhattachar 2026
Early study: 1.2–12 mg once weekly for 12 weeks with no step-up. Weight fell up to 11.3% more than on placebo, at 12 mg.
- Frequency
- Once weekly
- Route
- Subcutaneous injection (trials)
- Cycle
- Continuous in trials (12–48 weeks so far; phase 3 trials run 64 weeks).
Continuous, shown over 26 weeks
Common protocols
The ways Eloralintide is most often run, each tagged with where it comes from.
Step-up to 9 mg (phase 2)
Trial- Dose
- 3 → 6 → 9 mg, or 6 → 9 mg
- How often
- Once weekly
- How long
- 48 weeks
3 mg for 4 weeks, 6 mg for 4, then 9 mg: 16.5% loss, nausea in 25%. 6 mg for 20 weeks, then 9 mg: 19.9% loss, nausea in 54%.
Type 2 diabetes (phase 2)
Trial- Dose
- 3, 6 or 9 mg alone, or with tirzepatide
- How often
- Once weekly
- How long
- 48 weeks
Alone: 8.2–12.3% loss vs 3.0% on placebo; with tirzepatide, up to 23.3%, if all stayed on treatment (press release, September 2026).
Phase 3 (ENLIGHTEN)
Trial- Dose
- Four doses, not yet disclosed
- How often
- Once weekly
- How long
- 64 weeks
Trials in obesity, type 2 diabetes, sleep apnea, knee osteoarthritis pain, and added to an incretin drug; results expected from 2028.
Phase 2 step-up arm (3–6–9 mg)
| Period | Dose |
|---|---|
| Weeks 1–4 | 3 mg |
| Weeks 5–8 | 6 mg |
| Week 9 on | 9 mg |
Taking it
Where it goes
Injected under the skin once a week in trials. The papers don’t name the sites; weekly injections usually go in the belly, thigh or upper arm, rotated each week.
If you miss a dose
No label or published trial rule. Common practice with weekly injections is to take the next dose on schedule without doubling up. Its half-life of about two weeks means levels fall slowly after a missed dose.
What to expect
- Week 4
A single 12 mg dose lowered weight 4.4% vs a 0.6% gain on placebo in healthy adults.
Trial - Week 12
Weekly doses with no step-up lowered weight 2.6–11.3% more than placebo, most at 12 mg.
Trial - Week 48
9.4–20.1% mean loss vs 0.4% on placebo, if everyone had stayed on treatment. On 9 mg, 82% lost at least 10% of their weight vs 13% on placebo.
Trial - Week 48 (type 2 diabetes)
Alone: 8.2–12.3% loss and HbA1c down 1.1–1.4 points, vs 3.0% and 0.3 on placebo (press release, September 2026).
Trial
Side effects and what to do
Nausea (11–64% by dose vs 14% on placebo)
Highest when starting at 6 mg; 25% with the 3–6–9 mg step-up. Mostly mild to moderate. Ongoing vomiting needs medical advice.
Fatigue (0–46% by dose vs 12% on placebo)
Rose with dose (43% at 9 mg) and was lower with the slow step-up (21%). Report exhaustion that doesn’t ease.
Constipation (15% vs 6%) and diarrhea (15% vs 9%) across doses
Fluids and fiber help constipation. Don’t push through repeated vomiting or diarrhea.
Slower pulse (down 14.4 beats a minute at 12 mg over 12 weeks)
No symptoms in the early study, but slow heart rate was reported in 9 of 210 people at 48 weeks vs none on placebo. Dizziness or fainting needs checking.
Hair loss (7% vs 0% on placebo)
Most common at 9 mg (6 of 54). Whether the drug or the weight loss causes it isn’t known.
Stop and get medical help
Severe belly pain that won’t go away, repeated vomiting or signs of dehydration, fainting or a very slow pulse, thoughts of self-harm, or face or throat swelling or trouble breathing: get medical help.
Can it cause …?
The side effects people ask about most, answered one by one. Each answer says where it comes from.
- Tiredness
- TrialFatigue rose with dose in the 48-week trial: 43% at 9 mg and 46% on 6-then-9 mg vs 12% on placebo; 21% with the slower 3–6–9 mg step-up.
- Headache
- TrialHeadache: 6% on eloralintide vs 9% on placebo in the 48-week trial, but 12% vs 4% in a 12-week study of 100 people.
- Nausea or vomiting
- TrialNausea 11–64% by dose vs 14% on placebo at 48 weeks, highest when starting at 6 mg; vomiting 0–25% vs 0%. The slow step-up had 25% nausea.
- Diarrhea or constipation
- TrialConstipation 15% vs 6% and diarrhea 15% vs 9% on placebo, across all doses in the 48-week trial.
- Dizziness
- TrialDizziness: 4% on eloralintide and 4% on placebo in the 48-week trial.
- Trouble sleeping
- Not reportedTrouble sleeping wasn’t among common side effects (5% or more in any dose group) in the 48-week trial of 210 people on eloralintide.
- Hair loss
- TrialHair loss: 7% on eloralintide vs 0% on placebo in the 48-week trial, highest at 9 mg (11%).
- Acne, rash or skin changes
- TrialInjection-site reactions: 5% vs 6% on placebo in the 48-week trial. Rash wasn’t among common side effects.
- Water retention or swelling
- Not reportedFluid retention wasn’t among common side effects (5% or more in any dose group) in the 48-week trial of 210 people on eloralintide.
- Joint or muscle pain
- TrialJoint pain 4% vs 6% and back pain 3% vs 4% on placebo in the 48-week trial, so no more common than placebo.
- Anxiety, low mood or irritability
- TrialLow-mood events in 4 of 73 on it in a 12-week study (3 stopped). At 48 weeks: anxiety 3% vs 4% on placebo; one serious case of suicidal thoughts.
- Low or high blood sugar
- TrialLows weren’t a common side effect in people without diabetes. In type 2 diabetes, HbA1c fell 1.1–1.4 points (press release). Pramlintide warns of severe lows with insulin.
- Fast heartbeat or blood pressure changes
- TrialPulse fell 14.4 beats a minute at 12 mg vs 3.4 on placebo over 12 weeks. At 48 weeks, slow heart rate was reported in 9 of 210 vs none.
- More hunger
- TrialIt curbs appetite: decreased appetite 10% vs 4% on placebo in the 48-week trial. What happens to weight after stopping hasn’t been reported.
- Liver strain
- Not reportedLiver problems weren’t among common side effects in the 48-week trial of 210 people on it; people with liver disease other than fatty liver were excluded.
- Kidney problems
- TrialNot a common side effect; one serious acute kidney injury among 210 people on it in the 48-week trial. Dehydration from vomiting can strain the kidneys.
- Cancer risk
- PrecautionUnknown: trials have lasted up to 48 weeks, too short to judge, and no animal cancer studies have been published.
Trial: reported in human studies. Precaution: a concern that follows from how it works or from a related drug, not measured. Not reported: studied in people and not reported. A side effect that hasn’t been reported can still happen, especially with long or high-dose use. Any of these across every compound: the side-effect finder.
Who should avoid it
No product label covers eloralintide, so these come from human studies and from precautions based on how it works. Most important first.
- Pregnancy or breastfeeding
- PrecautionNo human safety data exist.
- Slow heart rhythm (bradycardia)
- TrialExcluded from the phase 2 trial. Eloralintide lowered the pulse by up to 14.4 beats a minute over 12 weeks, and slow heart rate was reported in 9 of 210 people vs none on placebo.
- Past suicide attempts or depression
- TrialPeople with past suicide attempts were excluded. In a 12-week study, 4 of 73 people on eloralintide had low-mood events; 3 on the top dose stopped, and their symptoms cleared in 2–4 days.
- History of pancreatitis
- TrialExcluded from the phase 2 trial, so its effect in people who have had pancreatitis is unknown.
- People on insulin or prone to low sugar
- PrecautionPramlintide, the approved amylin drug (discontinued in the US in 2025), has a boxed warning for severe low blood sugar with insulin. Eloralintide’s phase 3 diabetes trial excludes insulin users.
- Gastroparesis (very slow stomach emptying)
- PrecautionPramlintide is ruled out in gastroparesis because amylin slows stomach emptying. Eloralintide slowed emptying only briefly in a 12-week study, but people with gastroparesis haven’t been studied.
- Anyone relying on product quality
- PrecautionIt isn’t approved anywhere, so vials sold online have no regulated standard for identity, purity or sterility, and none has been tested in a trial.
Interactions
Only interactions stated on a product label or measured in a human study are listed.
- Medicines taken by mouth (tested with acetaminophen)
- TrialAfter the first injection, higher doses slightly lowered acetaminophen absorption, a sign of slower stomach emptying. By week 12 the effect had gone.
Trial: seen in human studies, or a group those studies left out. Precaution: follows from how it works or from a related drug, and hasn’t been tested. This isn’t a complete list: a pharmacist or doctor can check a specific medicine or condition. Every documented interaction, by medicine: drug interactions.
Special situations
What’s known about pregnancy, breastfeeding, kidney and liver problems, age and surgery. Where nothing has been studied, the row says so.
- Pregnancy
- PrecautionNo human safety data; trials required contraception. Approved weight-loss labels, such as Wegovy’s, say to stop once pregnancy is recognized.
- Breastfeeding
- PrecautionNo human data; it isn’t known whether it passes into breast milk.
- Kidney problems
- PrecautionNo results yet: a study in people with kidney impairment began in February 2026. One serious acute kidney injury occurred among 210 people in the 48-week trial.
- Liver problems
- PrecautionNo results yet: a study in people with different degrees of liver impairment began in February 2026. Trials excluded liver disease other than fatty liver.
- Older adults
- PrecautionThe 48-week trial took adults up to 75 (mean age 49); results by age haven’t been reported.
- Children and teens
- PrecautionNot approved for any age, and not studied in anyone under 18.
- Surgery and anesthesia
- PrecautionNo data. Eloralintide slowed stomach emptying only briefly in a 12-week study, but GLP-1 labels warn of stomach contents entering the lungs under anesthesia. Tell the surgical team about any injected compound.
Precaution: not studied, so the caution follows from how it works or from a related drug. Ages are given as approved or studied; this site never gives doses for children. Across every compound: pregnancy, breastfeeding, kidney disease, liver disease, older adults and surgery.
Tracking and pairing
Worth tracking
- Pulse (heart rate)
- Mood changes
- Hydration if vomiting or diarrhea is heavy
- Blood sugar if taking diabetes medicines
Often paired with
- Tirzepatide
Lilly’s planned combination: up to 23.3% loss at 48 weeks vs 14.8% on tirzepatide 15 mg alone in type 2 diabetes, with more stomach side effects (press release). Phase 3 is planned for late 2026.
Human studies
4 key published human studies, with how many people took part. Animal studies aren’t listed here.
-
Weight fell 9.4–20.1% vs 0.4% on placebo, if everyone had stayed on treatment; nausea and fatigue rose with dose.
- Design
- Randomized double-blind placebo-controlled trial (phase 2), adults with obesity or overweight without diabetes
- Dose
- 1, 3, 6 or 9 mg weekly, or stepped up to 9 mg
- Length
- 48 weeks
Billings et al., Lancet 2025, PMID 41207310
-
Eloralintide alone lowered weight 8.2–12.3% vs 3.0% on placebo, and up to 23.3% with tirzepatide, if everyone had stayed on treatment.
- Design
- Randomized double-blind placebo-controlled trial (phase 2), adults with type 2 diabetes; results by press release only
- Dose
- Eloralintide 3–9 mg weekly alone or with tirzepatide; tirzepatide 15 mg alone; placebo
- Length
- 48 weeks
Eli Lilly press release, September 2026 (NCT06603571)
-
Weight fell 2.6–11.3% more than on placebo; stomach side effects were uncommon, and pulse fell up to 14.4 beats a minute.
- Design
- Randomized placebo-controlled multiple-dose trial (phase 1), adults with obesity or overweight
- Dose
- 1.2, 3, 6 or 12 mg weekly with no step-up
- Length
- 12 weeks
Bhattachar et al., Diabetes Obes Metab 2026, PMID 41559929
-
Half-life was 13–15 days; 12 mg lowered weight 4.4% at 4 weeks vs a 0.6% gain on placebo.
- Design
- Randomized placebo-controlled single-dose trial (phase 1), healthy adults
- Dose
- 0.04–12 mg once
- Length
- Single dose, 4 weeks of follow-up for weight
Briere et al., Mol Metab 2025, PMID 41109426
Trials under way
Registered trials that are still running, or that finished without published results, most important first. Checked on ClinicalTrials.gov, October 7, 2026.
ENLIGHTEN-1: four eloralintide doses vs placebo for 64 weeks in about 1,980 adults with obesity or overweight without diabetes: weight change
Recruiting; main results expected March 2028
ENLIGHTEN-2: four doses vs placebo for 64 weeks in about 1,035 adults with type 2 diabetes and overweight: weight change
Recruiting; main results expected January 2028
ENLIGHTEN-6: eloralintide vs placebo added to a weekly incretin drug in about 900 adults with persistent obesity: weight change at 64 weeks
Recruiting; main results expected June 2028
ENLIGHTEN-3: eloralintide vs placebo in about 800 adults with obstructive sleep apnea and obesity: weight and breathing pauses at 64 weeks
Recruiting; main results expected March 2028
ENLIGHTEN-4: eloralintide vs placebo in about 900 adults with knee osteoarthritis pain and obesity: weight and knee pain at 64 weeks
Recruiting; main results expected March 2028
Every compound’s registered trials: trials under way.
Limits of the evidence
Eloralintide alone has been tested in a 48-week phase 2 trial of 263 adults without diabetes (210 got the drug), a two-part phase 1 study of 148 people, and a 48-week diabetes trial reported only by press release, all run by Eli Lilly. Five 64-week phase 3 trials began in 2025–2026 and report from 2028. Long-term safety, use in older adults or kidney or liver disease, and vials sold online are untested.
How it’s supplied
Weekly injections of 1–9 mg in phase 2 trials (up to 12 mg in early studies); phase 3 doses aren’t disclosed. Not sold as a medicine. Injected under the skin once a week in trials, either starting at the full dose or stepped up over 8–20 weeks. It’s available only in clinical trials, so the calculator and dose log don’t apply.
There’s no product to mix. Trial supplies aren’t sold, and vials listed online as eloralintide “for research” aren’t the trial product and haven’t been tested in people.
Datasheet
- Half-life
- about 13 to 15 days (310 to 366 hours) TrialSingle subcutaneous doses of 0.4 to 12 mg in healthy adults (phase 1); peak levels came 3 to 5.5 days after the dose.
- Type
- Peptide, 37 amino acids
- Molecular weight
- about 4,526 g/mol (calculated)
- Formula
- C201H319N49O65S2
- Sequence
- (γ-Glu)CNTATCATG(Orn)LAE(α-Me-Phe)LVRSSN(N-Me-Asn)FGPKLPPTEVGSNTY-NH2Cys2 and Cys7 joined by a methylene thioacetal bridge; Lys26 carries a C20 fatty diacid on two γ-Glu linkers
- Storage before use
- Not published for the trial product; no label exists.
- After mixing or opening
- Not published.
- Half-life: Briere et al., Mol Metab 2025, PMID 41109426
- Molecule: FDA GSRS, UNII 73G3354J8W (structure); PubChem CID 175663130 (formula, weight); Briere et al. 2025
- Storage: Community No label, manufacturer or published storage data exist for this compound
Every compound side by side: the half-life chart and the storage chart.
Identifiers
- CAS number
- 2883634-40-8
- UNII (FDA)
- 73G3354J8W
- PubChem CID
- 175663130
- ATC code
- None assigned
- Development codes
- LY3841136 (Eli Lilly)
- Brand names
- None; not approved anywhere. EloraTZP is Lilly’s working name for its combination with tirzepatide
- First described
- Discovered at Eli Lilly; first given to people in 2022; its design was published in 2025 (Briere et al.).
Every compound’s numbers: the identifiers table.
Product form and quality
No approved product exists, and trial supplies aren’t sold. Powder sold online as eloralintide has no regulated identity, purity or dose, and none has been tested in a trial; the trial product’s salt form and formulation haven’t been published.
Cautions
- Investigational and not approved anywhere; phase 3 results are expected from 2028.
- Nausea and fatigue rose with dose: up to 64% and 46% vs 14% and 12% on placebo in phase 2. Slower step-ups had fewer.
- It slows the pulse (by 14.4 beats a minute at 12 mg over 12 weeks); the phase 2 trial excluded people with slow heart rhythms.
- In an early study 3 of 36 people on 12 mg stopped after low-mood events; phase 2 excluded people with past suicide attempts.
- Vials sold online as eloralintide have no regulated standard for identity, purity or sterility.
Questions
What is eloralintide?
An investigational once-weekly injection that copies amylin, a fullness hormone the pancreas releases with insulin, and acts mainly on the amylin 1 receptor. It reduces appetite and food intake.
How does eloralintide work?
Eloralintide is a long-acting copy of amylin, a hormone the pancreas releases with insulin after meals. In cell studies it switched on the amylin 1 receptor about 12 times more strongly than the closely related calcitonin receptor. Natural amylin signals fullness to the brain and slows stomach emptying. In trials it lowered appetite and weight, and a fatty-acid chain keeps it in the blood for about two weeks. Whether its receptor selectivity means fewer side effects than other amylin drugs hasn’t been tested head to head, and why it slows the heart rate isn’t known. Safety beyond 48 weeks is unknown.
Is eloralintide FDA-approved?
Not approved in the US or anywhere else. Eli Lilly began phase 3 trials (ENLIGHTEN) in December 2025; none has reported yet. Never nominated for FDA’s 503A or 503B bulk lists and not in any of FDA’s compounding categories (lists updated May 2026 and March 2025). It isn’t part of any approved drug, so it can’t legally be compounded.
What is the usual eloralintide dose?
From human studies (Billings 2025): Obesity without diabetes (phase 2): 1, 3, 6 or 9 mg once weekly from the first dose, or stepped up to 9 mg (6 mg for 20 weeks, or 3 and 6 mg for 4 weeks each). At 48 weeks weight fell 9.4–20.1% vs 0.4% on placebo, if everyone had stayed on treatment. Type 2 diabetes (phase 2): eloralintide alone at target doses of 3, 6 or 9 mg weekly; all arms started at 1 or 3 mg. At 48 weeks weight fell 8.2–12.3% vs 3.0% on placebo, if everyone had stayed on treatment (Lilly press release, Sept 2026). These are the amounts sources reference, not recommendations.
How is eloralintide given?
Injected under the skin once a week in trials, either starting at the full dose or stepped up over 8–20 weeks. It isn’t sold: it’s available only in clinical trials.
Who should avoid eloralintide?
No product label covers eloralintide, so these come from human studies and from precautions based on how it works. Pregnancy or breastfeeding: No human safety data exist. Slow heart rhythm (bradycardia): Excluded from the phase 2 trial. Eloralintide lowered the pulse by up to 14.4 beats a minute over 12 weeks, and slow heart rate was reported in 9 of 210 people vs none on placebo. Past suicide attempts or depression: People with past suicide attempts were excluded. In a 12-week study, 4 of 73 people on eloralintide had low-mood events; 3 on the top dose stopped, and their symptoms cleared in 2–4 days. The “Who should avoid it” section lists 4 more groups and one interaction.
What is the half-life of eloralintide?
About 13 to 15 days (310 to 366 hours), measured in human studies. Single subcutaneous doses of 0.4 to 12 mg in healthy adults (phase 1); peak levels came 3 to 5.5 days after the dose.
How should eloralintide be stored?
Before mixing: Not published for the trial product; no label exists. After mixing: Not published. This is common practice; no product label covers it.
Is eloralintide banned in sport?
Probably. Not named on WADA’s 2026 list, but its S0 rule bans drugs with no current human approval anywhere, at all times.
Has eloralintide been studied in people?
Yes. The human studies section lists 4 published studies. The largest, from 2026, included 367 people. Eloralintide alone lowered weight 8.2–12.3% vs 3.0% on placebo, and up to 23.3% with tirzepatide, if everyone had stayed on treatment.
How long has eloralintide been studied in people?
Trial 48 weeks: 210 adults in the phase 2 obesity trial, plus eloralintide-alone arms of a 48-week diabetes trial reported by press release.
Does eloralintide come in other forms, like a pill or nasal spray?
Trial Only weekly injections under the skin have been tested in people. No oral, nasal or patch form has published human data.
Can you drink alcohol while taking eloralintide?
No study No data: no study has looked at alcohol with eloralintide.
Can eloralintide be taken with semaglutide or tirzepatide?
Trial Being developed with tirzepatide (a GIP and GLP-1 drug): up to 23.3% loss vs 14.8% on tirzepatide alone at 48 weeks (press release). A phase 3 trial tests adding it to a weekly incretin drug.
What happens if you take too much eloralintide?
Trial No label and no overdose data. Early studies gave single doses up to 12 mg and 12 weekly 12 mg doses; stomach upset, fatigue and a slower pulse were seen. Call Poison Help (1-800-222-1222), or emergency services for severe symptoms.
Sources
- Billings et al., eloralintide phase 2 trial (Lancet 2025) PMID 41207310
- Phase 2 trial results record: weight, side effects and dropouts by arm (ClinicalTrials.gov) NCT06230523
- Bhattachar et al., 12-week multiple-dose phase 1 study (Diabetes Obes Metab 2026) PMID 41559929
- Briere et al., discovery and single-dose phase 1 study (Mol Metab 2025) PMID 41109426
- Eli Lilly press release: eloralintide with tirzepatide in type 2 diabetes, phase 2 results (September 2026)
- ENLIGHTEN-1 phase 3 trial record (ClinicalTrials.gov, checked October 2026) NCT07321886
For the protocol details
- Eli Lilly press release: EloraTZP (eloralintide and tirzepatide) phase 2 results in type 2 diabetes (September 30, 2026)
- ENLIGHTEN phase 3 trial records (ClinicalTrials.gov, checked October 2026) NCT07282600
For how it works, who should avoid it and the limits of the evidence
- SymlinPen (pramlintide) prescribing information, boxed warning and contraindications (AstraZeneca)
For uses, the side-effect questions, special situations, trials, identifiers and status outside the US
- Wegovy prescribing information, sections 5.10 and 8.1 (Novo Nordisk, rev. 06/2026)
- FDA Global Substance Registration System record for eloralintide (UNII 73G3354J8W); PubChem CID 175663130
- ClinicalTrials.gov records for the ENLIGHTEN trials and the kidney and liver impairment studies NCT07426380 and NCT07401862 (checked October 8, 2026)
- WHO ATC index and Health Canada Drug Product Database searches (October 8, 2026); Australian Poisons Standard, October 2026